Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) have been given an average rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)’s stock price traded up 4.7% during mid-day trading on Thursday . The stock traded as high as $4.48 and last traded at $4.48. 1,401,726 shares were traded during mid-day trading, an increase of 7% from the average session volume of 1,304,263 shares. The stock had previously closed at […]
Mersana Therapeutics (MRSN) Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(Reuters) - Mersana Therapeutics Inc said on Monday the U.S. drug regulator had placed on hold an early-stage trial testing its experimental cancer dr.